ahk-cu

copper tripeptide for hair growth, riding GHK-Cu's reputation. thinner evidence, bigger marketing.

tier C · skin · topical hair regrowth signal

verdict

copper tripeptide for hair, inheriting GHK-Cu's 'copper peptide' marketing reputation without the receipts.

if you're asking how AHK-Cu compares to GHK-Cu — category capture. 'copper peptide' as a marketing label is genuinely earned by GHK-Cu (50+ studies, decades of cosmetic data). AHK-Cu inherits the reputation. the in vitro hair-follicle-stimulation work is real but small. the human clinical evidence for AHK-Cu specifically, at typical product concentrations, is single-group cosmeceutical studies dwarfed by the marketing.

if you're asking about AHK-Cu vs minoxidil / finasteride for hair loss — effect sizes are nowhere near minoxidil or finasteride. there is no legitimate protocol for systemic injection. as a cosmetic adjunct alongside minoxidil, plausible. as a standalone alopecia treatment, no. the chemistry is real, the biology is real, the marketing overreaches.

if you came in via injectable AHK-Cu vendor channels — topical is where the small clinical record sits. injectable AHK-Cu is the gray-market extrapolation from injectable GHK-Cu protocols (themselves under FDA review post April 2026). the safety signals for injectable copper peptides at scale are not established for either molecule. the GHK-Cu data does not transfer to AHK-Cu.

based on published evidence and disclosed clinical practice. not medical advice.

why C-tier

C-tier because the compound is real and has some plausible cosmetic utility, but the evidence for its headline marketed use (hair growth) is small and the way it's sold implies a much stronger case than the trial data supports. Not B-tier because the hair-growth evidence base is clearly thinner than B-tier compounds and the cosmetic effect sizes are modest. Not D-tier because the underlying chemistry is legitimate, the peptide does produce some measurable effects in small studies, and it doesn't fail or deceive at the basic pharmacology level. It just doesn't do nearly as much as it's marketed to do.

the core tension

AHK-Cu sits in the commercial shadow of GHK-Cu. GHK is in S-tier on this list because it has decades of skin-aging research, pharmaceutical-grade cosmetic integration, and a consistent mechanism. AHK-Cu is the hair-focused cousin, alanine-histidine-lysine with a copper ion, positioned as doing for hair what GHK does for skin. The biology is superficially similar (both are copper-transporting tripeptides with some histidine-mediated chelation), but the specific clinical evidence for AHK improving hair growth in humans is small, mostly single-group, and considerably less impressive than either GHK's skin evidence or what the marketing promises.

what it is

ahk-cu is a copper-chelated tripeptide, alanine-histidine-lysine bound to a copper ion. histidine provides the primary chelation site, the same motif that makes ghk-cu work. emerged from the broader copper-tripeptide research program that followed loren pickart's original ghk-cu work in the 1970s. classified as a cosmetic ingredient, present in numerous topical hair products.

what it does

in vitro work shows stimulation of hair follicle dermal papilla cells and growth-factor pathways. small clinical cosmeceutical studies report modest effects on hair density and shaft diameter when applied topically. effect sizes are nowhere near minoxidil or finasteride. there is no legitimate protocol for systemic injection.

origin

characterized in the cosmetic-research extension of pickart's copper-peptide program. the related ahk-linked tripeptide also has documented osteoblast-differentiation activity, which suggests the scaffold has real biology beyond the hair-growth marketing. supporting literature is mostly mechanistic plausibility from the broader copper-peptide class rather than direct ahk-cu trial data.

why researchers are interested

category capture. 'copper peptide' as a marketing label is genuinely earned by ghk-cu, and ahk-cu inherits the reputation without the receipts. it is also cheap and topical, so the floor of risk is low even if the ceiling of benefit is too.

does it work

the chemistry is real. the in vitro follicle effects are real. the human clinical evidence for ahk-cu specifically, at typical product concentrations, is small, single-group, and dwarfed by the marketing. as a cosmetic adjunct stacked with minoxidil, plausible. as a standalone alopecia treatment, no. real compound, real biology, overreaching claims. that is the whole c-tier story in one tripeptide.

claims vs the data

• copper-chelating tripeptide similar to GHK-Cu — supported — Structurally a copper-binding tripeptide with an analogous histidine-mediated chelation motif. The chemistry is genuine.
• stimulates hair follicle growth in humans — partially true — Small clinical cosmeceutical studies show modest effects on hair density or shaft diameter when AHK-Cu is applied topically. Effect sizes are typically small and the trials are not at the scale of minoxidil or finasteride evidence.
• equivalent or superior to GHK-Cu for skin — weak — GHK-Cu has vastly more research behind its skin applications. AHK-Cu is not a straightforward substitute for GHK-Cu in a skin context; it's a differently-positioned compound.
• treats androgenetic alopecia — overreach — Sometimes marketed this way. AHK-Cu has no evidence supporting it as a standalone treatment for male or female pattern hair loss. It's a cosmetic adjunct, not a hair-loss therapeutic.
• works synergistically with GHK-Cu — unverified — Combination products claim this. The specific synergy claim lacks the formal combination trials that would back it up.

key facts

• molecular formula: C15H26N6O4 (free peptide); typically formulated as Cu2+ complex
• molecular weight: 354.4 Da (free peptide)
• amino acids: 3
• half-life: short free-peptide plasma half-life; copper complex stability and topical penetration are the relevant pharmacokinetic properties in cosmetic use
• type: copper-chelated tripeptide (alanine-histidine-lysine)
• CAS: 66575-29-9
• 3 amino acids
• GHK-Cu's primary claim-to-fame frame (versus independent evidence)
• small size of dedicated AHK hair-growth trial literature
• 0 regulatory approvals for hair loss

frequently asked questions

What is AHK-Cu?

AHK-Cu is a tripeptide-copper complex (Alanine-Histidine-Lysine bound to copper). Developed by Loren Pickart's lab as a companion compound to GHK-Cu, targeted specifically at hair follicle biology. It is the less-researched sibling in the copper-peptide family.

What does AHK-Cu do?

Preclinical and cosmetic-industry studies suggest AHK-Cu stimulates hair follicle dermal papilla cells and supports hair growth signaling. Human clinical evidence is limited, typically in combination formulations with minoxidil or other actives. Most community use is topical for hair growth applications.

How is AHK-Cu typically administered?

Topical application is the primary use, incorporated in hair-growth serums and cosmetic formulations. There is no legitimate protocol for systemic injection. Cosmetic products typically contain AHK-Cu at low concentrations alongside other actives.

What are the side effects of AHK-Cu?

Topical AHK-Cu is well-tolerated at cosmetic concentrations. Occasional mild scalp or skin irritation. Systemic effects are uncommon given the topical use pattern.

Is AHK-Cu FDA approved?

No. AHK-Cu has no FDA drug approval. It is classified as a cosmetic ingredient and is legal in hair-care and skincare products. Not marketed as an injectable research chemical the way many peptides are.

How much does AHK-Cu cost?

Topical AHK-Cu hair-growth products retail at modest cosmetic prices depending on formulation and brand. Research-grade AHK-Cu powder for DIY topical formulation is inexpensive on the research-chemical market.

related peptides

• ghk-cu — S-tier parent copper peptide with far stronger skin evidence base
• klow — A-tier blend containing GHK-Cu
• snap-8 — other cosmetic peptide with overreach claims

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.